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millions. CONCLUSIONS: Hip and knee arthroplasties represents an important 
amount of investment for both public and private health care systems in Brazil. 
These are initial data to be used in future studies to determine the cost-
effectiveness and budgetary impact of different therapies linked to this 
procedure in Brazil.  
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OBJECTIVES: Osteoarthritis is characterized by joint pain and mobility 
impairment associated with the gradual wearing of cartilage. Osteoarthritis 
poses a substantial and increasing burden on society as a result of impaired 
health-related quality of life and the socio-economic impact. In Russia, there are 
no solid estimates of the magnitude of the condition. This study is aimed to 
assess co-morbidity, quality of life (QOL), work/productivity loss, and medical 
resource utilization in Russian urban adults with osteoarthritis. METHODS: 
Patients’ self-reported data were collected from 2011 National Health and 
Wellness Survey (NHWS). Survey samples represented major urban areas in 
Russia. QOL was measured by the physical component score (PCS) and mental 
component score (MCS) of the Short Form-12 (SF-12). Loss of work productivity 
was measured by the Work Productivity and Activity Impairment instrument. 
Medical resource utilization was measured by health care provider, ambulance 
request and hospitalization in the past 6 months. RESULTS: Of the 10,039 adult 
respondents, 733 (7.3%) were diagnosed with osteoporosis (2.2% not diagnosed 
with osteoarthritis and 88.1% have not experienced arthritis at all). Average age 
of patients diagnosed with osteoarthritis was 54.1 years. Diagnosed osteoarthritis 
group reported more co-morbidities (sleep difficulties 51%, high blood pressure 
46%, pain 44%, insomnia 37%, arrhythmia 30%, high cholesterol 21%), lower 
mean scores of PCS (40.4 vs.47.3) and similar MCS (43.3 vs.43.8). More patients 
visited health care providers (83% vs.70%), and a higher percentage were 
hospitalized (17% vs. 9%) over the past 6 months compared to those not 
experiencing arthritis. Furthermore, osteoarthritis group reported 37.6% 
impairment in daily activity compared to 25.3% of those not experiencing 
arthritis. All mentioned differences were statistically significant (p<0.05). 
CONCLUSIONS: From Russian NHWS results, patients diagnosed with 
osteoarthritis suffer from impairment in QOL, work/productivity loss and more 
co-morbidities. Findings indicate there is still an unmet medical need in Russian 
osteoarthritis patients.  
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Stevens CA1, Miller KL1, Gisby M2 
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OBJECTIVES: American patient consumers spend in excess of $1B annually on 
drugs to treat Arthritis. Osteoarthritis is a condition that can lead to Rheumatoid 
Arthritis. This study looks at how public and private payers in the United States 
might cover the use of Chondroitin Sulfate with Glucosamine for treating 
Osteoarthritis. METHODS: Published coverage policies for products used to treat 
Osteoarthritis (OA) were gathered and analysed, along with primary data 
developed through payer interviews. Interviewees selected included pharmacy 
directors at private payers and those who administered Medicare Part D plans 
(N=3). RESULTS: Findings show that payers would provide coverage of 
chondroitin sulfate with glucosamine for Osteoarthritis if: a) The cost were less 
than $100/month; b) The Centers for Medicare and Medicaid Services (CMS) 
provides coverage; c) Data demonstrated improved outcomes over treatments 
like omega-3-acid ethyl esters and niacin tablet, film-coated extended-release. 
Payers also indicated that they would afford chondroitin sulfate with 
glucosamine with Tier 2 formulary status, similar to that of omega-3-acid ethyl 
esters and niacin tablet, film-coated extended-release. CONCLUSIONS: Based on 
our research, we believe US Medicare Part D plans and private payers would 
cover chondroitin sulfate and chondroitin sulfate with glucosamine products 
provided there is clinical data demonstrating its efficacy in OA patients, and 
assuming that CMS would approve this product as an exception to its coverage 
policy for nutritional supplements. All payers expressed that currently there are 
limited or no treatment options for OA patients, implying that a product that 
shows some statistically significant benefit will be covered and reimbursed by 
them. If clinical data shows efficacy in some or all OA patients, we believe the 
market could provide for a significant price premium as compared to current 
OTC products.  
 
PMS67  
FREQUENCY OF OUTPATIENT PHYSIOTHERAPY SERVICES IN TRAUMA 
DISEASES IN HUNGARY  
Molics B1, Kránicz J1, Schmidt B2, Sebestyén A3, Ágoston I1, Cs. Horváth Z4, Marada G1, 
Boncz I1 
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3National Health 
Insurance Fund Administration, Pécs, Hungary, 4National Institute for Quality- and 
Organizational Development in Healthcare and Medicines, Pécs, Hungary  
OBJECTIVES: The aim of our study is to assess the amount, frequency, and the 
health insurance expenses related to trauma diseases within out-patient care. 
METHODS: The data come from the financial data base of the National Health 
Insurance Fund Administration (in Hungarian: OEP) involving the year of 2009. 
The health procedure activity list was provided by the rulebook on the 
application of the activity code list in out-patient care. The trauma syndromes 
were reported in diagnosis code S00-S99. RESULTS: Trauma injuries account for 
3471657 cases in the annual number of the physiotherapy-related activities 
(32318413 cases) showing an approximately 10.5% prevalence. The 20 most 
frequent treatments accounts for 86.3 % (2997907) of total services. The following 
top-10 medical procedure were responsible for 68.14% (2365569) of total 
activities: individual training (10.95 %), muscle strengthening exercise (9.0 %), 
stretching of contractura (8.13), mobilization of joints (7.24 %), exercises against 
resistance (7.02 %), training for circulation improvement (6.4 %), exercise to 
prevention of cardiovascular complications (6.05%), passive movement of 
physical landscape (4.94%), gymnasztics (4.22%), Parts of the body per individual 
physiotherapy (4.17). Physiotherapy out-patient care for trauma patients were 3.4 
million cases with 901 million Hungarian Forint (3,2 million Euro) health 
insurance subsidy CONCLUSIONS: The 20 most commonly used activities out of 
151 with 86,3% incidence shows a varied content. The list of the 20 most 
frequent types of services reflects to the demand for the combination of active 
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OBJECTIVES: The aim of our study is to assess the utilization of out-patient care 
physiotherapy services related to trauma diseases according to age and gender. 
METHODS: The data come from the financial data base of the National Health 
Insurance Fund Administration (in Hungarian: OEP) involving the year of 2009. 
The OENO activity list was provided by the rulebook on the application of the 
activity code list in out-patient care. The trauma syndromes were reported 
according to WHO ICD diagnosis code S00-S99. We analyzed the medical 
procedures according to the Hungarian versions of the WHO “International 
Classification of Procedures in Medicine”. We analyzed the utilization of 
physiotherapy services according to age and gender. RESULTS: Trauma injuries 
account for 3471657 cases within the annual number of the physiotherapy-
related activities (32318413 cases) showing an approximately 10.5% prevalence. 
Increasing with age, the number physiotherapy procedures per 10000 population 
is on the rise with a national mean value of 3386. There is no significant 
difference between the mean values in both genders (females=3272, 
males=3349). The highest number of physiotherapy treatment is provided for the 
men patients in the age group 55 to 59 (4525) followed by age groups of 35 to 45 
with 4225 and 4272 cases. The oldest women age group show the highest value 
in this gender (7664), followed by age groups of 75 to 85 with 6057 and 6041 cases 
per 10000. The number of injury-related cases are higher in men until 49 years of 
age, but over 50 years of age is higher for women. CONCLUSIONS: In case of the 
traumatic injuries, the highest demand of the outpatient care physiotherapy 
services occurred older injured patients. The claim indicators were significantly 
higher for men and women over 50 years of age.  
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OBJECTIVES: The aim of our study is to assess amount and frequency of the 
physiotherapy services in the different regions of trauma diseases within out-
patient care. METHODS: The data come from the financial data base of the 
National Health Insurance Fund Administration (in Hungarian: OEP) involving 
the year of 2009. The OENO activity list was provided by the rulebook on the 
application of the activity code list in out-patient care. The trauma syndromes 
were reported according to WHO ICD diagnosis code S00-S99. We analyzed the 
medical procedures according to the Hungarian versions of the WHO 
“International Classification of Procedures in Medicine”. The distribution of 
physiotherapy procedures were calculated accroding to major body parts. 
RESULTS: The total number of the 151 different types WHO-classified 
physiotherapy procedures was 32318413 in the year of 2009; and 3471657 (10.5%) 
of them related to trauma care with the ICD code group S00-S99. The amount 
and frequency of the physiotherapy services are in the 10 different trauma 
regions are the following: injuries of the head 57 615 (1.66%), neck 27683 (0.80%), 
thorax 67720 (1.95%), abdomen, lower back, lumbar spine and pelvis 73857 
(2.13%), shoulder and upper arm 697896 (20.10%), elbow and forearm 656537 
(18.91%), wrist and hand 466360 (13.43%), hip and thigh 353260 (10.18%), knee and 
lower leg 794326 (22.88%), ankle and foot 276403 (7.96%). CONCLUSIONS: The 
annual number of extremity injuries is the highest, while that of the torso, neck 
and head injuries is the smallest. Most cases treated in the region of the knee 
and leg, followed by the region of the upper extremity. In case of capacity 
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OBJECTIVES: To describe the use of biologics, in the treatment of rheumatoid 
arthritis (RA), in a real life Canadian setting. METHODS: Patients covered by the 
Quebec provincial drug reimbursement program (RAMQ) who had a diagnosis of 
RA and had used at least one biologic in the period from January 1, 2001 to June 
30, 2011 were selected. Agents included in the study were adalimumab, 
etanercept, infliximab, abatacept, anakinra, golimumab, rituximab, tocilizumab 
and ustekinumab, as they were all reimbursed by the drug program. The use of 
biologics was analyzed in terms of patient characteristics, treatment patterns 
and costs. RESULTS: A total of 4225 patients were included in this study. The 
average age was 51.1 years (SD=14.6), and there was a higher proportion of 
women (69.9%). About two-thirds of patients (63.3%) had only a diagnosis of RA, 
while 36.7% had two or more concomitant diagnoses, such as psoriasis (15.9%) 
and psoriatic arthritis (11.5%). During the course of the study period, most 
patients used only one biologic (78.3%). The number of biologic scripts increased 
by an annual rate of 25% over the last 5 years; from 12,926 scripts in 2006 to 
26,491 in 2010. Out of the total 135,616 scripts for a biologic, 74,058 were for 
etanercept (54.6%), 27,994 for adalimumab (25.9%), and 23,858 for infliximab 
(17.6%). Concomitant use of methotrexate decreased over time from 60.3% in the 
first year following initiation of the biologics to 44.2% in the fourth year. Average 
annual cost for biologics was $17,040 per patient and did not vary significantly 
over time. CONCLUSIONS: RA is a complex disease. More than a third of the 
patients studied had concomitant inflammatory diseases. Biologics use 
increased over time, and there was a marked reduction in the use of 
concomitant methotrexate four years after biologic initiation.  
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INHALED CORTICOSTEROID (ICS) USE IN NURSING HOME (NH) RESIDENTS 
WITH COPD  
Zarowitz BJ1, O'Shea T2 
1Omnicare, Inc., Cincinnati, OH, USA, 2Omnicare, Inc., Englewood, OH, USA  
OBJECTIVES: The prevalence of COPD in NH residents is 10-20%. While ICS use 
occurs commonly, there are concerns about adverse consequences of therapy. 
Our goal was to develop a profile of NH residents with COPD, and to identify 
differences in outcome markers in residents receiving ICS versus those not 
receiving ICS. METHODS: Pharmacy claims and Minimum Data Set (MDS) 2.0 
data from January 1, 2009 to September 30, 2009 and October 1, 2009 to 
September 3, 2010 were extracted from Omnicare Senior Health Outcomes, then 
linked and de-identified. A profile of residents with COPD was developed using 
descriptive analyses. Residents receiving ICS were matched to residents not 
receiving ICS on age, gender, tobacco use, and prevalence of diabetes mellitus, 
respiratory infection, osteoporosis, pneumonia, hip fracture, and “other” 
fracture. One year change from baseline within subsets was assessed using Chi-
square analyses primarily. Linear logistic regression was used to compare 
baseline-adjusted outcomes between subsets. RESULTS: Fifty-nine percent of NH 
residents with COPD had full MDS and pharmacy data available (24,733/41,598). 
Of these, 4000 ICS-receiving and 4000 non-ICS-receiving residents were matched. 
The ICS subset generally showed higher cognition, memory, and functioning (all 
p=0.001) comparatively. The non-ICS subset demonstrated higher incidence of 
Alzheimer’s disease, other dementia, and greater cognitive impairment (all 
p=0.001), while shortness of breath, anxiety, glaucoma, pneumonia, oxygen 
therapy, and at least 1 hospital stay were more common in the ICS subset (all 
p<0.05). The 1 year change in ICS subset showed a significant increase in the 
adjusted odds ratio of “other” fracture (non-hip) when compared to the non-ICS 
subset {OR 1.44 [1.07, 1.94], p=0.016)}. CONCLUSIONS: Our analysis indicates NH 
residents with COPD receiving ICS may be at greater risk of non-hip fracture. 
Research focusing on a longer-term horizon, duration of ICS treatment, and 
recommended use of ICS is needed to further understand the consequences of 
ICS use.  
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LONG-ACTING BETA-AGONISTS AND ASTHMA EXACERBATIONS REQUIRING 
SHORT COURSES OF ORAL CORTICOSTEROIDS: A MULTI-CATEGORY EXPOSURE 
MARGINAL STRUCTURAL MODELS ANALYSIS  
Ali AK1, Hartzema AG2, Hendeles L2, Lu X2, Winterstein AG2, Segal R2 
1Eli Lilly and Company, Indianapolis, IN, USA, 2University of Florida, Gainesville, FL, USA  
OBJECTIVES: To evaluate asthma-related morbidity in patients exposed to long-
acting beta-agonist (LABA) bronchodilators as monotherapy, inhaled 
corticosteroids (ICS) monotherapy, and ICS/LABA combination therapy. 
METHODS: The Clinical Practice Research Datalink (formerly the General Practice 
Research Database, GPRD) was used to apply marginal structural models for the 
evaluation of asthma-related morbidity measured by prescriptions for short 
courses oral corticosteroids (OCS) within 12 months of initiating LABA, ICS, or 
ICS/LABA in a cohort of asthamtic adults. Asthma severity was measured by the 
following variables during 12 months before LABA initiation (prescription for 
OCS, asthma-related visits to hospitals or emergency departments, and number 
of prescriptions for inhaled short-acting beta-agonists [SABA]); and the following 
variables at the initiation and during 12 months after (prescription for SABA, and 
number of asthma drug classes prescribed). RESULTS: A total of 51,103 asthmatic 
adults were followed for 12 months after receiving first prescription for study 
drugs from January 4, 1993 to August 20, 2010. About 92% initiated ICS 
monotherapy, 1% initiated LABA monotherapy, and 7% initiated combination 
therapy. Among ICS/LABA combination therapy initiators, 78% were in single-
device formulations and 22% were in separate-devices. Compared with ICS 
monotherapy, LABA monotherapy is associated with 10% increased risks of 
asthma exacerbations requiring short courses of OCS (HR, 1.10; 95%CI, 1.07-1.18). 
Initiators of ICS/LABA combination therapy are respectively 62% and 50% less 
likely to receive prescriptions of OCS for asthma exacerbations than initiators of 
ICS (HR, 0.38; 95%CI, 0.12-0.66) or LABA monotherapies (HR, 0.50; 95%CI, 0.14-
0.78). CONCLUSIONS: Inhaled LABA should not be prescribed as monotherapy to 
adults with asthma, and should be uased as an add-on to ICS as maintenance 
therapy. The findings suggest presence of time-dependent confounding by 
asthma severity in the assessment of LABA association with asthma 
exacerbations requiring prescriptions of OCS.  
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DISEASE BURDEN OF IDIOPATHIC CHRONIC COUGH (ICC) AND CHRONIC 
COUGH (CC) IN COPD, IPF AND LUNG CANCER (LC): AN EXPLORATORY 
LITERATURE REVIEW  
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OBJECTIVES: Chronic cough (CC) accounts for 10–38% of all referrals to 
respiratory physicians (Morice, 2007). Some patients suffer CC related to lung 
cancer (LC), chronic obstructive pulmonary disease (COPD) and idiopathic 
pulmonary fibrosis (IPF). Additionally a proportion of patients with CC with no 
explanatory etiology remains symptomatic despite treatment and is classified as 
suffering idiopathic chronic cough (ICC). To understand the burden of CC and 
ICC, a systematic literature search was conducted on the epidemiology, natural 
history, humanistic and economic burden. METHODS: A systematic search 
strategy was implemented in MEDLINE, EMBASE, Cochrane HTA and NHS Centre 
for Review and Dissemination databases to identify relevant English language 
publications on the burden of cough since 2002. RESULTS: 1447 publications 
were identified in the search and an additional 10 from bibliographic review. Of 
these 98 articles were selected for further review using pre-defined inclusion 
criteria. The reported prevalence of CC varies between countries (9 to 33%); very 
limited information on CC in LC, COPD, IPF and ICC was found. Prolonged 
hypersensitivity of the cough reflex has been proposed as a mechanism, partly 
explaining resistance to treatment of CC and ICC. Patients’ quality of life 
deteriorates due to insomnia, urinary incontinence, social disability or 
depression. Only one economic evaluation investigating the cost effectiveness of 
managing CC of unknown etiology was identified. It demonstrated that empirical 
treatment is the cheapest management option for CC, while cough management 
involving diagnostic procedures recommended by American College Chest 
Physicians is the most expensive option. CONCLUSIONS: The published 
literature on CC and ICC is extremely limited. Further research is needed to 
understand the humanistic and economic burden of these conditions and 
implement proper disease assessment. However, appropriate diagnosis  
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OBJECTIVES: The impact of macitentan, a novel endothelin receptor antagonist, 
on PAH-related hospitalizations was evaluated in the SERAPHIN trial 
(NCT00660179). METHODS: PAH patients aged ≥12 years in WHO functional class 
(FC) II-IV were randomized 1:1:1 to oral macitentan 3 or 10mg, or placebo once-
daily. Time to either death due to PAH or hospitalization for PAH up to end  
of treatment (EOT), a secondary endpoint, and time to hospitalization for PAH up 
to EOT were evaluated via Cox proportional hazards regression and log rank 
tests. Annual rates of PAH-related hospitalizations and inpatient hospital days 
up to EOT (pharmacoeconomic endpoints) were adjusted post hoc using negative 
binomial regression for baseline FC (I/II vs. III/IV) and 6-minute walk distance 
(>380 vs ≤380 m). RESULTS: The 742 patients (76% female, median age 45 [range 
12-85] years) were mostly in FC II (52%) or III (46%). Median treatment duration 
was >2 years. Risk of death due to PAH or hospitalization for PAH was reduced by 
33% with macitentan 3mg (HR 0.67, 97.5% CI 0.46-0.97, P=0.0146) and 50% with 
macitentan 10mg (HR 0.50, CI 0.33-0.75, P<0.0001) versus placebo. Risk of 
hospitalization for PAH was reduced by 39% with macitentan 3mg (HR 0.61,  
CI 0.42-0.90, P=0.0040) and 50% with macitentan 10mg (HR 0.50, CI 0.34-0.76, 
P=0.0001). Of the patients randomized to placebo, macitentan 3mg and 10mg, 
33% (n=82), 24% (n=59), and 21% (n=50), respectively, had ≥1 hospitalization  
for PAH. Annual rates of PAH-related hospitalizations and inpatient hospital 
days were reduced by 43% (treatment-effect ratio [TER] 0.57, 95% CI 0.38-0.86, 
P=0.0068) and 33% (TER 0.67, CI 0.33-1.37, P=0.2707), respectively,  
with macitentan 3mg, and by 55% (TER 0.45, CI 0.30-0.69, P=0.0002) and 52% (TER 
0.48, CI 0.24-0.97, P=0.0416), respectively, with macitentan 10mg versus  
placebo. CONCLUSIONS: Significant reductions in these hospitalization 
endpoints demonstrate that macitentan improves long-term PAH-related health 
outcomes.  
